AIMS: Evaluation of the efficacy of gabapentin in patients undergoing out-patient treatment for opiate withdrawal. DESIGN: A 3-week double-blind, randomized, placebo-controlled trial of adjunctive gabapentin in methadone-assisted detoxification (MAD). SETTING: Specialized Addictive Behaviors Unit, an out-patient unit for the treatment of patients with an addictive disorder serving the city of Isfahan (Iran). PARTICIPANTS: Forty out-patients, 37 males and three females, aged 21-61 years, who met DSM-IV criteria for opiate dependence. INTERVENTION: Random assignment of subjects to receive adjunctive treatment with either gabapentin (900 mg/day) or placebo under double-blind conditions. MEASUREMENTS: Severity of subjective withdrawal symptoms using the Subjective Opiate Withdrawal Scale at six stages. FINDINGS: Despite the superiority of gabapentin on controlling some of withdrawal symptoms, no significant differences were reported between two groups. CONCLUSIONS: Dosage of 900 mg/day of gabapentin is not significantly superior to placebo in controlling opiate withdrawal symptoms.
RCT Entities:
AIMS: Evaluation of the efficacy of gabapentin in patients undergoing out-patient treatment for opiate withdrawal. DESIGN: A 3-week double-blind, randomized, placebo-controlled trial of adjunctive gabapentin in methadone-assisted detoxification (MAD). SETTING: Specialized Addictive Behaviors Unit, an out-patient unit for the treatment of patients with an addictive disorder serving the city of Isfahan (Iran). PARTICIPANTS: Forty out-patients, 37 males and three females, aged 21-61 years, who met DSM-IV criteria for opiate dependence. INTERVENTION: Random assignment of subjects to receive adjunctive treatment with either gabapentin (900 mg/day) or placebo under double-blind conditions. MEASUREMENTS: Severity of subjective withdrawal symptoms using the Subjective Opiate Withdrawal Scale at six stages. FINDINGS: Despite the superiority of gabapentin on controlling some of withdrawal symptoms, no significant differences were reported between two groups. CONCLUSIONS: Dosage of 900 mg/day of gabapentin is not significantly superior to placebo in controlling opiate withdrawal symptoms.
Authors: Giovanni Addolorato; Lorenzo Leggio; F Woodward Hopf; Marco Diana; Antonello Bonci Journal: Neuropsychopharmacology Date: 2011-10-26 Impact factor: 7.853
Authors: Nichole C Sanders; Michael J Mancino; W Brooks Gentry; J Benjamin Guise; Warren K Bickel; Jeff Thostenson; Alison H Oliveto Journal: Exp Clin Psychopharmacol Date: 2013-07-15 Impact factor: 3.157